Funding Opportunities

Supports an integrated team science approach to discovering the causes of Parkinson's disease through the Morris K. Udall DCWoW program, extending the existing Udall Centers of Excellence by enabling collaborative, discovery-focused research not possible via standard grant mechanisms. Note that this is a forecasted Notice of Intent.

Supports extramural biomedical and human performance research and development through the U.S. Army Medical Research Acquisition Activity (USAMRAA), open to any eligible entity including universities, nonprofits, and businesses, with awards ranging from $750K to $50M. This is a multi-year rolling BAA covering FY23–FY28.

Planning grant for investigators new to the CCRP field to build foundational knowledge, skills, collaborations, and preliminary data on shared mechanisms of skin injury caused by chemical threats, with emphasis on vesicants and other chemicals of concern rather than clinical trials.

Supports basic and applied research proposals in areas of interest to the Army Applications Lab (AAL), welcoming submissions from universities, nonprofits, businesses, and foreign organizations focused on disruptive technologies and applications with Army relevance. This is a rolling BAA open to up to 1,000 expected awards across a wide range of science and technology research areas.

Supports research and development of medical countermeasures, enabling technologies, life cycle bioinformatics, and improved logistics tracking across the chemical, biological, radiological, and nuclear defense mission areas, welcoming proposals from educational institutions, nonprofits, and private industry. This is a rolling BAA under which unsolicited proposals may be submitted at any time while the announcement remains active.

BARDA’s primary funding mechanism for medical countermeasures across pandemics, CBRN threats, and emerging infectious diseases.

BARDA DRIVe mechanism supporting early-stage, high-impact health security innovations with phased funding up to ~$20M.

Supports foundational basic and applied scientific research proposals submitted to the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL), spanning research areas from basic research through advanced technology development to help achieve Army overmatch in future conflicts. This is a consolidated rolling BAA open to universities, nonprofits, businesses, and foreign organizations.

Supports military-civilian partnerships (MCPs) at high-acuity trauma centers by enabling military trauma teams to provide full-time trauma and acute care alongside civilian counterparts, with the goal of improving the nation's response to public health and medical emergencies. Up to 30 eligible 501(c)(3) hospitals/trauma centers may receive awards from the $4 million total program funding pool.

Supports basic research to inform toxicology of chemical warfare agents and toxic industrial chemicals with primary or secondary effects on the nervous system, generating results to elucidate toxicity mechanisms and advance therapeutic countermeasures for civilian mass exposure situations. This active grant program (PAR-25-077) is from NINDS/NIAID, with application due dates in September 2025 and 2026.

Supports basic and applied research across a broad range of soldier-focused science and technology areas including combat feeding, soldier protection and survivability, textile technologies, biomechanics, human factors, aerial delivery, simulation and training, and biotechnology. This rolling BAA is open to proposals from any eligible entity and covers the full spectrum of soldier effectiveness and expeditionary maneuver support research.

Supports cutting-edge, often disease-agnostic research programs through ARPA-H's Health Science Futures mission office, seeking solution summaries and proposals that remove scientific and technological limitations to advance the healthcare of the future through translational, real-world impact. Submissions are accepted on a rolling basis via the ARPA-H solutions portal at solutions.arpa-h.gov.

Supports fundamental research — across grants, cooperative agreements, and other transactions — aimed at countering chemical, biological, radiological, nuclear, and explosive (CBRNE) threats, with a total program funding pool of $500 million open to any eligible entity. This is a long-term rolling BAA.

Supports fundamental engineering research in neuroengineering, rehabilitation robotics, brain-inspired assistive or rehabilitative systems, theoretical or computational methods, and novel models of functional recovery that advance knowledge benefiting individuals with disabilities. This active NSF program (DARE) has standard deadline cycles for high-risk, high-reward proposals.

Supports basic, applied, and advanced AI research and development through the Army Artificial Intelligence Integration Center (AI2C), seeking whitepapers and proposals from universities, nonprofits, businesses, and foreign organizations on new technologies and translational approaches that advance Army AI capabilities. This is a forecasted opportunity.

Provides prestigious, multi-year funding to early-career faculty who demonstrate strong potential to integrate innovative research with impactful education. It supports the development of future academic leaders by requiring projects that combine scientific advancement with teaching, outreach, and broader societal benefits.

Supports extramural biomedical research through a rolling broad agency announcement from the U.S. Army Medical Research and Development Command (USAMRDC), welcoming pre-applications and full proposals from eligible organizations on an ongoing basis. This is a multi-year BAA open to submissions across a wide range of military medical research topics.

Supports action-oriented research under the NIH HEAL Initiative that accelerates the translation of evidence-based addiction prevention, treatment, and recovery interventions into routine practice, addressing the opioid crisis and overdose deaths across individual, provider, community, and system levels.

Supports the commercialization of "deep technologies" rooted in foundational science and engineering discoveries by providing NSF-funded researchers with entrepreneurial education, mentoring, and funding to assess product-market fit and accelerate the translation of basic research into emerging products, processes, and services.

Supports rigorous mechanistic clinical trials investigating how mind and body interventions — such as mindfulness meditation, yoga, acupuncture, and massage — impact emotional well-being and its relationship to whole person health, using a two-phased R61/R33 funding mechanism.

Supports the development of non-addictive analgesic therapeutics, including small molecules and biologics, to treat pain and address the opioid crisis. It focuses on advancing promising candidates through optimization and early clinical development, using a milestone-driven, collaborative approach to prepare for human studies.

Supports research on nutrition across the lifespan, with a focus on addressing social determinants of health to improve outcomes and reduce disparities. It emphasizes rigorous, nursing-informed research to advance equitable nutrition and health for diverse populations.

Invites proposals for basic and applied research to advance science and technology for Navy and Marine Corps needs. It supports innovative, high-impact projects across a wide range of disciplines to enhance military capabilities and operational effectiveness.

Supports research on improving health systems to better integrate treatment for co-occurring opioid use disorder and chronic pain. It focuses on collaborative care models, implementation strategies, and scaling sustainable, integrated care delivery across health settings.

Support the advanced development and enhancement of emerging informatics technologies to improve data acquisition, analysis, and interpretation across the cancer research continuum. It prioritizes high-impact, user-friendly tools with strong plans for community engagement, dissemination, and adoption, targeting technologies beyond early prototyping but not yet widely used.

Support the advanced development and enhancement of emerging informatics technologies to improve data acquisition, analysis, and interpretation across the cancer research continuum. It prioritizes high-impact, user-friendly tools with strong plans for community engagement, dissemination, and adoption, targeting technologies beyond early prototyping but not yet widely used.

Supports implementation of investigator-initiated, high-risk clinical trials, including associated mechanistic studies. It provides comprehensive support for trial execution, including recruitment, data management, regulatory activities, and analysis to ensure successful completion and impact.

Supports U.S. small businesses in developing innovative health-related technologies through phased research and development, including clinical trials. It aims to advance projects aligned with NIH and CDC missions, encouraging collaborative, high-impact solutions with commercialization potential.

Provides SBIR Phase I, Phase II, and related grant funding to eligible U.S. small business concerns to support innovative R&D aligned with the research missions of NIH, CDC, and FDA across a broad range of health and biomedical science areas. Note that this is a forecasted opportunity and applications are not yet being solicited — publication is contingent upon reauthorization of the SBIR program.

Supports a comprehensive strategy for human performance science and technology research through the Air Force Research Laboratory (AFRL) and U.S. Air Force School of Medicine (USAFSAM) CHEERS Multiple Authority Announcement (MAA), covering research from basic science to technology maturation and transition. This active DoD Air Force program (FA238424S2233) covers research in human enabling, enhancing, restoring, and sustaining capabilities.

Supports research across all technical areas under the Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) program, soliciting white papers (and potentially later proposals) from any eligible entity on experimental and developmental efforts in human effectiveness topics for national defense.

Supports development of targeted drug-delivery strategies to reach hard-to-access sites in the body, such as the brain, placenta, retina, or tumors. It focuses on using microphysiological systems to optimize delivery, evaluate biodistribution and off-target effects, confirm therapeutic activity, and identify the best route of administration.

Supports research on how environmental exposures influence gut-brain signaling to drive neurological conditions, including mental health and neurodegenerative diseases. It aims to develop gut-focused interventions and biomarkers to improve detection, prevention, and treatment of these conditions through multidisciplinary approaches.

Supports the development and translation of extracellular vesicle (EV)-based therapeutics for regenerative medicine applications. It focuses on advancing innovative EV technologies, including engineered and off-the-shelf therapies, to improve tissue repair and regeneration.

Supports innovative research in bioinformatics, translational bioinformatics, and computational biology to advance methods for analyzing complex biomedical data. It emphasizes the use of cutting-edge technologies like AI and machine learning to generate actionable insights that improve health outcomes.

Supports development of advanced non-invasive or minimally invasive imaging technologies to visualize the human olfactory system with high spatial and temporal resolution. It encourages multidisciplinary approaches to overcome current limitations in accessing and studying olfactory structures, with the goal of improving understanding and diagnosis of olfactory disorders.

Supports small businesses in advancing previously funded projects toward commercialization through later-stage R&D, regulatory activities, and technical assistance. It focuses on bridging gaps not covered by earlier SBIR/STTR phases, helping technologies move closer to market readiness and real-world application.

Supports innovative approaches to advance therapeutic development for ultra-rare cancers, including pediatric and molecularly defined subsets. It emphasizes collaborative data infrastructure, novel clinical endpoints, real-world evidence, and innovative trial and treatment strategies to overcome challenges in developing therapies for small patient populations.

Offers funding for military nursing research and evidence-based practice projects focused on operational readiness, trauma care, and healthcare delivery in austere or combat environments. It supports a range of award types, including large research grants, rapid-response projects, and smaller EBP initiatives to improve military health outcomes.

Supports military nursing research and evidence-based practice (EBP) projects through the TriService Nursing Research Program (TSNRP), with initial and follow-on research awards up to $500,000 and EBP projects up to $200,000. This active program has rolling deadlines for military nursing research applications.

Supports high-priority, time-sensitive military nursing research projects through the TriService Nursing Research Program (TSNRP) FY25 RAPID High Priority Awards, providing rapid funding for emerging nursing research needs across the Department of Defense. This active program supports applied military nursing science with expedited review and funding cycles.

Supports research and surveillance of travel-associated infectious diseases through a collaborative network of travel and tropical medicine providers. It aims to improve detection, prevention, and clinical management by generating actionable data to inform public health guidance and patient care.

Supports research to prevent and mitigate severe respiratory illness by studying epidemiology, prevention, treatment, and long-term outcomes of respiratory pathogens. It aims to strengthen preparedness infrastructure and improve public health and clinical outcomes, particularly for high-risk populations.

Supports programs to strengthen global health security by improving the capacity of public health systems to prevent, detect, and respond to disease outbreaks worldwide. It focuses on building partnerships and enhancing surveillance, reporting, and response capabilities to mitigate emerging public health threats.

Supports research to develop and test causal hypotheses linking human behaviors to oral and systemic health outcomes in individuals with chronic conditions. It emphasizes multidisciplinary approaches to identify underlying mechanisms and generate findings that can inform future clinical interventions and disease management strategies.

Supports interdisciplinary, data-driven research to uncover the molecular and cellular mechanisms underlying resilience to Alzheimer’s disease and related dementias. It emphasizes integrating genomic, epidemiologic, and mechanistic approaches to identify predictors of resilience across diverse populations.

Supports establishment of a translational center to advance the use of digital health technologies data in Alzheimer’s disease and related dementias research. It focuses on developing infrastructure, tools, and best practices to enable secure integration, sharing, and reuse of multi-modal data for translational and clinical applications.

Supports preclinical and clinical research on the discovery and development of high-impact interventions — including medications and medical devices — to prevent and/or treat substance use disorders and overdose, with the goal of advancing candidate interventions toward regulatory approval or clinical adoption. This opportunity uses the two-phased UG3/UH3 cooperative agreement mechanism, with awards up to $3 million.

Supports multidisciplinary groups of scientists conducting clinical research on sensory and communication disorders through the NIDCD Clinical Research Center Grant (P50), advancing diagnosis, prevention, treatment, and amelioration of hearing, balance, smell, taste, voice, speech, and language disorders. This active grant program (PAR-25-445) uses standard application due dates.

Supports the development of computational tools, theories, models, and analytical methods for understanding dynamic brain circuits and neural computations — spanning from neurons to behavior — that will be made broadly accessible to the research community. The program aims to advance fundamental understanding of brain function and organization, with applications toward treatments for brain disorders such as Parkinson's disease and major depressive disorder.

Supports advanced development and validation of emerging technologies for cancer research, building on prior feasibility to enable broader adoption. It focuses on refining and rigorously validating innovative tools and methods that enhance cancer detection, diagnosis, treatment, and research capabilities.

Supports institutions in establishing Nutrition Obesity Research Centers (NORCs) that provide shared research infrastructure, pilot funding, and collaborative programs to enhance multidisciplinary research in nutrition and obesity. The goal is to improve the efficiency, productivity, and impact of existing research programs through coordinated core services and innovation support.

Supports research on how specific stroke events contribute to cognitive impairment and dementia in post-stroke populations, with the goal of identifying underlying mechanisms and risk factors. It is a limited competition for prior awardees, emphasizing collaborative, multidisciplinary studies to improve understanding and outcomes of post-stroke vascular cognitive impairment.

Supports the translation of laboratory discoveries into therapeutics for visual system diseases through a milestone-driven, phased approach. It focuses on advancing promising candidates through preclinical development toward IND/IDE submission and readiness for clinical trials.

Supports multidisciplinary collaborations that apply bioengineering approaches to solve biomedical and clinical problems. It focuses on developing, optimizing, and translating innovative tools and technologies to advance basic, translational, and clinical research.

Supports state-of-the-art, investigator-initiated translational research through P50 SPORE grants aimed at improving prevention, early detection, diagnosis, and treatment of organ-specific or related human cancers. The program funds research that must stem from human biology and include a translational endpoint within the project period, with an estimated total funding pool of $25 million across approximately 12 awards.

Supports multidisciplinary urology research centers that foster collaboration and serve as national resources for advancing urologic science. It aims to drive impactful research through coordinated efforts across institutions and disciplines.

Provides researchers access to biospecimens from major longitudinal studies to investigate genetic, environmental, and substance-related influences on health across the lifespan. It aims to maximize the scientific value of these datasets by supporting studies that advance understanding of brain development, substance use, and disease risk.

Provides seed funding to support early-stage and new investigators conducting innovative research at the intersection of substance use, HIV/AIDS, and related fields. It aims to generate preliminary data and new concepts that can lead to larger, more comprehensive research projects.

Supports the development of an entrepreneurship training program that teaches life science researchers—particularly in substance use disorder research—how to translate scientific discoveries into viable biomedical products. The program focuses on early-stage innovation skills such as commercialization, market analysis, intellectual property, and funding pathways to help researchers move ideas toward real-world impact.

Supports research education programs that enhance the scientific training and research skills of psychiatry residents. It aims to build a stronger mental health research workforce through innovative, research-focused educational experiences.

Supports the development of innovative short courses to train students, trainees, and early-career investigators in cutting-edge mental health research methods. It aims to enhance research skills and capacity through educational programs focused on emerging tools, techniques, and approaches.

Supports highly collaborative center-based research in basic neuroscience and translational mental health to advance understanding of brain, behavior, and severe mental illness. It emphasizes integrated, high-impact teams using innovative approaches to uncover mechanisms of psychopathology and improve the scientific foundation for mental health research.

Provides access to a state-of-the-art Biological Testing Facility to support development of new contraceptive methods and reproductive health therapies. It is intended for investigators with innovative, validated approaches that are ready to advance toward future clinical development.

Supports clinical research projects that advance trial readiness for rare diseases by enabling the efficient movement of candidate therapeutics or diagnostics toward clinical trials, including through the development of rigorous biomarkers, clinical outcome assessment measures, or characterization of rare disease presentation and course. The goal is to increase the likelihood of success for future rare disease clinical trials.

Supports research evaluating the effectiveness of digital health technologies for remotely managing type 2 diabetes through clinical trials. Projects should test multi-component digital approaches to improve diabetes care, outcomes, and patient management.

Supports discovery and mechanistic research to advance understanding of cardiovascular disease in type 1 diabetes through a continuation of the CARE-T1D consortium, leveraging multi-omics and molecular approaches. This forecasted NOFO uses the U01 cooperative agreement mechanism.

Supports the formation of a Disorders of Gastrointestinal Interoception Consortium (DGIC) to advance research on GI motility disorders, including gastroparesis, through multidisciplinary clinical research centers using state-of-the-art technologies to identify biomarkers and novel therapeutic targets. This forecasted NOFO (RFA-DK-27-117) anticipates funding up to 6 Clinical Research Centers via cooperative agreement, with an estimated application deadline of November 1, 2026.

Supports the establishment of NIBIB Technology Development Network Coordinating Centers that bring together scientific and engineering communities to solve translational problems, facilitating collaborations across technology development projects and advancing innovative platform technologies for biomedical research. This forecasted NOFO (RFA-EB-26-001) uses the U24 cooperative agreement mechanism with an estimated application deadline of August 1, 2026.

Supports the continuation of the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers, leveraging patient cohorts, biospecimens, and data science to characterize genetic, clinical, and environmental factors in IBD development and advance precision medicine. This forecasted NOFO (RFA-DK-27-116) uses the cooperative agreement mechanism, anticipates up to 9 awards totaling $6.4M, with an estimated application deadline of November 1, 2026.

Supports the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) by establishing a Data Coordinating Center (DCC) that manages participant enrollment, biospecimen collection, data coordination among Genomic Research Centers, and submission of data to central repositories. This forecasted NOFO (RFA-DK-27-124) uses the cooperative agreement mechanism with an estimated 1 award totaling $1.6M and a deadline of November 1, 2026.

Supports establishing a Scientific Data Research Center (SDRC) to coordinate collaboration among Clinical Research Centers, manage enrollment, biospecimen processing, and data submission to central repositories.

Supports global detection, notification, and response through partnerships with Ministries of Health and CDC country offices. This forecasted cooperative agreement (CDC-RFA-JG-26-0113) anticipates 2 awards totaling $15M.

Supports early-stage investigators of exceptional creativity to propose novel, original, and insightful vision research with high impact potential through the NEI New Innovator Award (DP2 mechanism). This forecasted grant (PAR-26-087) anticipates 4 awards.

Supports interdisciplinary research networks through the U24 mechanism to advance biomedical research on resilience and health optimization, foster cross-training and collaborations, and generate preliminary data through small-scale pilot projects. This forecasted cooperative agreement (RFA-AT-26-001) anticipates 3 awards totaling $1.5M.

Supports interdisciplinary teams forming Centers of Excellence in Genomic Science (CEGS) to address challenging biomedical questions from a genomics perspective, developing highly innovative concepts, methods, tools, and technologies not achievable by standard R01s. This forecasted cooperative agreement (PAR-26-036) anticipates 2 awards totaling $5M.

Supports dissemination of NHGRI-funded genomic technologies by funding integrated toolkits containing reagents, hardware, annotated protocols, computational pipelines, and hands-on training to lower barriers to adoption of novel genomic tools by the scientific community. This forecasted grant (PAR-26-037) anticipates up to 15 awards with a ceiling of $50K each.

Supports the commercialization of "deep technologies" rooted in foundational science and engineering discoveries by providing NSF-funded researchers with entrepreneurial education, mentoring, and funding to assess product-market fit and accelerate the translation of basic research into emerging products, processes, and services. The program is open to U.S. institutions of higher education, with awards starting at $50,000 from a total program pool of $12 million.

Supports rigorous mechanistic clinical trials investigating how mind and body interventions — such as mindfulness meditation, yoga, acupuncture, and massage — impact emotional well-being and its relationship to whole person health, using a two-phased R61/R33 funding mechanism. The R61 phase establishes feasibility benchmarks, followed by the R33 phase for full-scale trials contingent on successful milestone completion.

Solicits innovative biological research that leverages novel biological processes to enhance protection and capabilities of U.S. warfighters. It emphasizes high-risk, high-impact approaches that go beyond incremental improvements to current technologies.

Supports a pilot program to develop and apply AI models to address the complexity and heterogeneity of diabetes. It focuses on integrating data science and biomedical expertise to create, validate, and disseminate AI tools that accelerate diabetes research and enable more personalized approaches.

Seeks to fund approximately 5 awards totaling ~$3.745M to support a national network of centers providing resources, expertise, and pilot funding to advance nonmalignant hematology research.

Supports development of SCENT III electronic nose technologies that use volatile organic compound (VOC) signatures from human skin to create a noninvasive, real-time diagnostic platform for disease diagnosis and monitoring. This forecasted cooperative agreement (RFA-TR-26-001) uses NCATS Cures Acceleration Network authorities.

Supports development and validation of advanced 3-D tissue models for drug screening that structurally, biochemically, and mechanically mimic human tissue, requiring applicants to utilize the NCATS 3-D Bioprinting laboratory infrastructure. This forecasted cooperative agreement (RFA-TR-25-016) anticipates 2 awards totaling $1.6M.

Supports research determining whether and how breakthrough AI systems affect patient safety and how AI can be safely implemented in healthcare settings, balancing AI's potential to improve safety and efficiency against risks of patient harm. This active AHRQ grant program (PA-24-261) uses standard application due dates.

Supports individuals conducting dissertation research as part of an accredited doctoral program, providing AHRQ funding to advance health services research undertaken to qualify for a research doctorate degree. This active AHRQ grant program (PA-23-196) uses standard application due dates.

Supports development, testing, and evaluation of strategies and interventions to improve diagnostic safety and quality in the heterogeneous ambulatory care environment, addressing AHRQ's goal of improving patient safety through diagnosis. This active AHRQ grant program (PA-23-290) uses standard application due dates.

Supports intensive mentored research career development for individuals with clinical doctoral degrees through didactic study and mentored research in health services research, providing salary and research support for 3-5 years to launch independent research careers. This active AHRQ grant program (PA-22-232) uses standard application due dates.

Supports research focused on understanding and improving diagnostic safety in ambulatory care by investigating the incidence and contributory factors of diagnostic errors across the array of ambulatory care services. This active AHRQ grant program (PA-23-291) uses standard application due dates.

Supports system-level research approaches to improve patient safety by improving healthcare worker safety and well-being, recognizing that patient safety cannot be fully achieved without addressing the safety and well-being of healthcare professionals. This active AHRQ grant program (PA-24-093) uses standard application due dates.

Supports health services research demonstration and dissemination grant applications (R18) focused on AHRQ priorities including improving healthcare quality, patient safety, healthcare delivery, practice improvement, and whole-person healthcare delivery across all settings and populations. This active AHRQ grant program (PA-24-156) uses standard application due dates.

Supports research building evidence about the characteristics and value of primary care that influence patient outcomes and advance health equity, such as care coordination, continuity, comprehensiveness, and trust, and how these can be improved to strengthen primary healthcare. This active AHRQ grant program (PA-24-205) uses standard application due dates.

Supports research advancing fundamental, process-level, and systems-level understanding of the Arctic's rapidly changing natural environment, social and cultural systems, including Arctic Natural Sciences, Arctic Social Sciences, Arctic System Science, Arctic Observing Network, and Polar Cyberinfrastructure. This active NSF solicitation (NSF 23-572) supports U.S. investigators studying the Arctic region and its connectivity with lower latitudes.

Supports novel cutting-edge study designs using machine learning, artificial intelligence, and adaptive methods to discover individual-level health and function profiles that could enable personalized prevention plans for cognitive and brain health in older adults. This forecasted NIA grant program aims to advance precision aging research.

Supports various research and development projects across U.S. Army Corps of Engineers Engineer Research and Development Center (ERDC) laboratories including Coastal and Hydraulics, Geotechnical, Environmental, Information Technology, Cold Regions, Construction Engineering, and Geospatial Research. Active BAA (W912HZ26S0001) with application due date of January 1, 2027.

Supports improving the health and well-being of individuals with traumatic brain injuries (TBI) by streamlining access to critical resources, services, and supports, including information and referral services, resource facilitation, outreach and awareness, and screening and trainings to community stakeholders. This forecasted ACL grant program (HHS-2026-ACL-AOD-TBSG-0019) anticipates approximately 31 awards.

Supports multidisciplinary centers to determine 3-dimensional structures of molecules and molecular complexes involved in priority infectious diseases including HIV, focusing on biomolecular complexes that can be targeted to develop new medicines and diagnostic tests to prevent or treat infections. This forecasted NIAID cooperative agreement (RFA-AI-27-009) anticipates future announcement.

Supports individual scientists or groups proposing bold, groundbreaking, unconventional research with potential to create new scientific paradigms, establish new clinical approaches, or develop transformative technologies across any biomedical science area, with no preliminary data required. This forecasted NIH grant (RFA-RM-26-003) has an estimated deadline of January 21, 2026.

Supports a Clinical Research Network on Antimicrobial Resistance (AMR) to design, implement, and manage clinical research addressing key AMR clinical questions, including treatment limitations from resistant infections in vulnerable populations such as those with diabetes and cancer. This forecasted NIAID cooperative agreement (RFA-AI-27-005) has an estimated deadline of January 14, 2026.

Funds rolling Mini Evidence-Based Practice (EBP) projects, providing equipment and supplies to support military nurse-led EBP operational projects that foster warfighter readiness and military nursing care. Applications are accepted on a rolling basis through August 31, 2026, pending available funding.

Seeks to enable researchers to access its Biobank biospecimens for assays evaluating associations between biomarkers and chronic diseases, supporting precision medicine through biomarker discovery, validation, disease stratification, and multiomics integration. This forecasted opportunity supports the program's mission to accelerate research by leveraging data from over 1 million enrolled participants.

Funds innovative, high-impact research to better understand, prevent, diagnose, and treat lupus while improving quality of life for individuals living with the disease. Award mechanisms include Idea Award, Impact Award, Transformative Vision Development Award, and Transformative Vision Award, supporting diverse research from basic science to clinical interventions.

Funds high-impact research to optimize health and well-being for all people affected by arthritis, with a new Translational Research Award for FY26 alongside the Clinical Research Award. Focus areas include prevention and early diagnosis, and treatment and mitigation of disease progression and burden.

Supports research to prevent, detect, treat, cure, and improve survival from ovarian cancer for Service Members, Veterans, and all affected women. Award mechanisms include Clinical Trial Award, Investigator-Initiated Research Award, Ovarian Cancer Academy Early-Career Investigator Award, and Pilot Award.

Investigates seizure mechanisms, comorbidities, novel treatment approaches, and quality of life outcomes across epilepsy and related neurological conditions, with particular focus on post-traumatic epilepsy. Covers basic neuroscience and genetic causes through clinical trials and patient-centered outcomes research.

Addresses musculoskeletal injuries, disorders, and reconstructive needs spanning bone, cartilage, tendon, joint, and soft tissue repair in active duty and veteran populations. Spans basic, translational, and clinical research on trauma, degenerative disease, and regenerative strategies.

Advances understanding of autism spectrum disorder etiology, early identification, co-occurring conditions, and evidence-based interventions across the lifespan. Encompasses neurodevelopmental mechanisms, environmental factors, service delivery, and family and community outcomes.

Investigates traumatic brain injury, post-traumatic stress, and co-occurring psychological health conditions relevant to military service members and veterans. Addresses neuroscience of injury and recovery, diagnostic tools, behavioral health treatment, and rehabilitation strategies across the TBI severity spectrum.

Addresses a broad spectrum of diseases and conditions with direct relevance to military and veteran populations, including infectious diseases, rare disorders, and chronic conditions not covered by other dedicated programs. Supports research from basic discovery through clinical investigation across multiple therapeutic areas.

Two ambitious projects focused on rigorous functional validation of newly identified therapeutic targets for Alzheimer’s disease–related dementias, with the goal of de-risking translational research and accelerating development of new therapies. This forecasted opportunity favors cross-disciplinary teams able to build and validate target-modulation tools, models, and protocols in a phased, milestone-driven framework.

Small pilot projects that advance the Human Virome Program by validating and improving virome-related tools, expanding relevant cohorts or biospecimen sampling, and studying interactions between the human virome and host health. It is best suited to focused, collaborative projects that complement rather than duplicate existing consortium efforts and can deliver meaningful results on a limited scope with modest resources.

Opportunities for projects with strong clinical relevance, particularly those advancing safe and effective macromolecular, cellular, translational, and clinical approaches that improve function and quality of life across the lifespan. Key fit is research with preliminary data and clear impact potential—either high-risk, high-reward therapeutic development targeting primary DMD pathology or preclinical/clinical studies that strengthen trial readiness, evaluate long-term outcomes, and improve care.

Supports high-impact research focused on developing durable community resources, advancing effective treatments and cures, and improving understanding of the causes and progression of bone marrow failure diseases. Best aligned with translationally relevant, hypothesis-driven projects or shared resource efforts that can build on strong scientific rationale and, depending on the mechanism, preliminary data to move the field toward meaningful clinical and research impact.

Supports continuation-stage, high-readiness projects aimed at closing critical military medical capability gaps in infectious disease prevention and treatment, hemorrhage and trauma care, temperature-related injuries, musculoskeletal injury support, and radiation countermeasures. It is best suited for advanced translational, technology development, or clinical efforts that build directly on prior Department of War-funded work and are positioned to deliver near-term impact for military medicine rather than support new or basic research.

Supports research to predict, diagnose, and treat health effects of military-related toxic exposures, including areas like neurotoxins, Gulf War Illness, and burn pits via three funding mechanisms.

Supports research to understand, diagnose, treat, and restore vision following military-related eye injuries, including care in austere environments using three funding mechanisms.

Supports a collaborative network to develop and clinically test novel therapies for glioblastoma, including agents that can cross the blood-brain barrier. It aims to accelerate drug development from late preclinical stages through early-phase clinical trials to improve treatment outcomes.

Supports early-stage development of innovative technologies for cancer research, focusing on proof-of-concept studies for new tools, assays, and platforms. It emphasizes high-impact, technically novel approaches that can enhance cancer detection, diagnosis, treatment, and overall research capabilities.

Supports enhancing bioengineering and biomedical imaging research capacity at Historically Black Colleges and Universities (HBCUs). It aims to strengthen innovation, training, and partnerships to increase competitiveness and advance technological development in health research.

Supports expansion of the NExUS Collaboratory to study neural cell populations and circuits involved in addiction and substance-related behaviors. It focuses on generating and integrating multimodal datasets, developing analytical tools, and advancing understanding of how neural ensembles encode addiction-related processes.

Supports exploratory, collaborative research on brain and nervous system disorders across the lifespan, with a focus on partnerships between U.S. and low- and middle-income country institutions. It aims to advance scientific understanding and develop innovative, cost-effective interventions addressing neurological and mental health conditions globally.

Provides early-stage investigators with a single, flexible grant to support all research within their lab aligned with NIGMS priorities. It aims to enhance funding stability, reduce administrative burden, and enable innovative, high-impact scientific research.

Addresses acute injury intervention, secondary health effects, psychosocial issues, and rehabilitation & regeneration across the spectrum of traumatic spinal cord injury. Spans preclinical and clinical research from early-stage discovery through clinical trials.

Advances research on neuropsychiatric disorders, tumor and cyst prevention, epilepsy, diagnostics/therapeutics, and maternal-fetal health in tuberous sclerosis complex. Encompasses multi-organ manifestations of TSC across the clinical translational spectrum.

Investigates the causes, prevention, diagnosis, treatment, and quality of life in multiple sclerosis with emphasis on neuroimmunology, neuroprotection, and myelin repair. Supports bench-to-bedside research advancing understanding of MS pathogenesis and novel therapeutic approaches.

Addresses melanoma prevention, early detection, treatment resistance, metastasis, immunotherapy response, and survivorship. Advances translational and clinical research from preclinical mechanisms through patient-relevant outcomes including rare melanoma subtypes.

Advances understanding of sensorineural hearing loss, tinnitus, and vestibular dysfunction with focus on restoration and prevention strategies relevant to noise-exposed and aging populations. Encompasses molecular, cellular, and translational research on inner ear biology and auditory neuroscience.

Supports applied research BAA focused on developing technologies for detection, protection, and response to CBRN threats.

Addresses critical gaps in biodefense and public health preparedness by advancing novel biological tools, detection platforms, diagnostics, and medical countermeasures. Targets high-priority biothreat agents and naturally occurring pathogens with potential for mass casualty events requiring innovative rapid-response solutions.

Supporting innovative, high-impact research with clinical relevance, this congressionally directed program funds efforts to decrease risk, slow progression, and ease symptoms of Parkinson's disease. Administered by the Defense Health Agency, it encourages investigators to explore a wide range of biological, clinical, and therapeutic approaches across both preclinical and human research.

Fostering basic research that offers significant benefits to national warfighting and peacekeeping capabilities, this Air Force Office of Scientific Research opportunity supports work across engineering, information science, physical science, and biological science. Research is conducted within Air Force, university, and industry laboratories, with the goal of ensuring results transition to meet U.S. Air Force needs.

The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing.

Calls for innovative, high-impact research with clinical relevance to increase survivability and readiness of the Warfighter. Requires submission of a pre-application through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline, with full application submission by invitation only.

Supports innovative, high-impact rare cancer research with clinical relevance across areas such as tumor biology, preclinical model development, therapy, and AI/ML-enabled research. Funds both exploratory concepts and more advanced efforts that can improve research resources, trial readiness, and outcomes for people with rare cancers.

Supports high-impact kidney cancer research spanning disease biology, risk factors, screening and diagnosis, rare kidney cancers, therapeutics, survivorship, and patient outcomes. Funds both early-stage innovative concepts and more developed studies aimed at improving care for kidney cancer patients.

Funds efforts to expand access to preventive health services for women and girls by strengthening screening programs, improving early detection, and enhancing care delivery systems across diverse and underserved settings. It is best aligned with integrated approaches that combine service delivery, workforce training, and community engagement to improve health outcomes.

Supports initiatives to strengthen laboratory capacity, surveillance systems, and workforce expertise to improve detection, diagnosis, and response to fungal diseases, including emerging and drug-resistant threats. It is best aligned with multidisciplinary efforts that address gaps in global health infrastructure and coordination.

Funds bio-behavioral surveillance among populations disproportionately affected by HIV, generating data on risk behaviors, testing patterns, and prevention service use to inform public health strategies. It is best aligned with rigorous, community-engaged approaches that support targeted interventions and program planning.

Supports research to understand and treat neurofibromatosis types 1, 2, and schwannomatosis, including tumor biology, clinical interventions, and quality of life outcomes. Funds translational and clinical studies advancing diagnosis, treatment, and prevention of NF-related complications.

Supports prostate cancer research across data science, early-career investigator development, innovative high-risk/high-gain ideas, and mentored physician research. Includes mechanisms for quantitative analysis of complex datasets, career-building projects for emerging researchers and clinicians, and impactful studies that advance prostate cancer knowledge without supporting clinical trials.

Supports development of broadly protective influenza vaccines that combine seasonal efficacy with pre-pandemic protection against emerging influenza threats. Ideal projects focus on universal or next-generation vaccine strategies, novel immune targets, adjuvants, delivery approaches, and enabling technologies that strengthen pandemic preparedness while maintaining commercial viability in the seasonal influenza market.

Supports the development of a fully automated, man-portable, and ruggedized prototype platform for on-demand, expeditionary manufacturing of clinical-quality nucleic acid primers and probes. The system must be designed for operation in far forward or austere environments by non-specialist personnel, with a performance period not to exceed 24 months.

AFOSR's open BAA for basic research across Air Force priorities including engineering, information science, and physical and biological sciences. Supports university, nonprofit, and industry proposals aligned with national warfighting and peacekeeping capabilities.

DARPA rolling solicitation inviting innovative basic research concepts across all technical offices, including the Biological Technologies Office (BTO) and Defense Sciences Office (DSO). Abstracts accepted on a rolling basis through June 2027.

FY26 pre-announcement from the CDMRP Reconstructive Transplant Research Program. The Concept Award supports highly innovative, untested concepts in vascularized composite allotransplantation (VCA); letter of intent required, no preliminary data, no clinical trials.

CDC Global Health Center NOFO to strengthen global public health laboratory systems - biorisk management, laboratory workforce, quality management, emergency preparedness, and diagnostic/genomic sequencing capacity for pathogens of pandemic potential. Up to 3 awards; $25M total.

Focuses on lung cancer prevention, early detection, molecular characterization, treatment resistance, and survivorship, with emphasis on military-relevant occupational and environmental exposures. Advances translational and clinical research from preclinical biology through therapeutic intervention and quality of life outcomes.

Supports prototype-stage solutions that address military readiness, operational medicine, infectious disease threats, musculoskeletal injuries, pain management, and force health protection. Ideal projects have demonstrated feasibility, align with a specific military capability gap, and are focused on advancing deployable products, clinical solutions, or knowledge products rather than early-stage basic research.

Funds basic research, discovery, and preclinical development of highly effective vaccines for malaria and potentially other mosquito-borne diseases. Supports novel vaccine design approaches, including structure-based immunogen design and combination vaccines, to reduce parasite infection and malaria disease burden.

Supports development of objective, personalized sleep technologies that detect and respond to health-relevant sleep patterns in real time. Ideal projects combine advanced sensing, analytics, and intervention capabilities to improve sleep quality, health outcomes, and performance through scalable home-based solutions that move beyond traditional sleep monitoring.

Supports development of high-performance antigen testing technologies that enable rapid, sensitive, and multiplexed infectious disease detection at the point of care. Ideal projects focus on advancing deployable diagnostic platforms, integrated testing systems, and enabling technologies that bridge the performance gap between traditional immunoassays and molecular diagnostics.

Supports academic-industrial partnerships that move promising scientific and engineering advances toward practical technologies and methods for disease research, risk assessment, detection, prevention, diagnosis, treatment, and management. It is best suited to collaborative translational projects that can pair academic innovation with industry development expertise to advance tools with clear potential for use in preclinical, clinical, or broader research and care settings.

For teams that already have a working biomarker assay on human specimens and need to take it through analytical validation first, then clinical validation, so it can be used as an investigational assay in future cancer trials or studies. It is a good fit for later-stage assay validation projects with a clear cancer-related clinical context, strong multidisciplinary support, quantitative go/no-go milestones, and access to well-annotated specimens, but it is not for biomarker discovery, early technology development, or conducting a clinical trial itself.

Funds exploratory basic research on biological/genetic mechanisms of cancer health disparities in racial/ethnic and other underserved populations, with no clinical trials allowed and should clearly test biological mechanisms tied to disparities using relevant underserved-population biospecimens/models/datasets, and avoids nonresponsive topics like projects without a cancer disparities focus, age/sex disparities alone, or non-biological behavioral/social studies.

Supports basic, mechanistic research on the biological and genetic drivers of cancer health disparities, including studies of cancer biology and prevention, new models and methods, and secondary data analyses. It is best suited to innovative projects that can deepen understanding of disparity-related mechanisms while also strengthening the research tools, resources, and scientific workforce needed to advance this field.

Funds research partnerships between academic investigators and industry (U01) to develop bioengineering solutions, leveraging industry resources and expertise to address complex biomedical challenges. Applications must propose collaboration between at least one academic researcher and one industry partner to advance bioengineering technologies toward clinical application.

Advances development of fit-for-purpose candidate biomarkers and composite biomarker panels for neurological and neuromuscular disorders, targeting more efficient clinical trials and improved clinical care decisions. Encompasses biomarker identification, confirmation using human samples or data, and clinical validation across disease settings.

Supports investigators with validated starting compounds to discover and develop novel in vivo chemical probes for brain targets relevant to the missions of NIA, NEI, NIDA, and NIMH, advancing understanding of biological processes and disease mechanisms in the nervous system. Clinical trial not allowed.

Supports early-stage, engineering-driven projects that test the feasibility and potential utility of new or improved bioengineering solutions for biomedical research, clinical care delivery, or accessibility challenges within the missions of NCI and NIDCR. It is best suited to innovative, multidisciplinary projects that generate proof-of-feasibility or preliminary development data for promising technologies, methods, or tools that could lead to meaningful advances in capability, performance, cost, or access.

Supports development of innovative technologies to enable acquisition of biomedical knowledge, including instruments, software, algorithms, reagents, and engineered biological tools, with emphasis on advancing proof-of-concept approaches into validated working prototypes. Best suited for high-risk projects focused on overcoming significant technical barriers and demonstrating broad utility, rather than applying the technology to specific biological questions.

Seeks to enable researchers to access its Biobank biospecimens for assays evaluating associations between biomarkers and chronic diseases, supporting precision medicine through biomarker discovery, validation, disease stratification, and multiomics integration. This forecasted opportunity supports the program's mission to accelerate research by leveraging data from over 1 million enrolled participants. (U01 Clinical Trial Not Allowed)

Supports development and testing of non-pharmacological, multi-level interventions to improve sleep health and address sleep-related disparities among populations experiencing health inequities. Best suited for rigorously designed, community-informed projects that target behavioral, social, environmental, or health system factors and examine sleep as a pathway to broader health improvement.

Advancesearly exploratory, proof-of-concept studies on mechanisms by which bariatric surgery affects cancer risk, specifically to attract bariatric surgery researchers to study cancer-related outcomes rather than short-term endpoints like weight loss or diabetes.

Advances understanding of acute burn care, wound healing, scarring, reconstructive techniques, long-term functional recovery, and the psychological impact of burn injuries in military populations. Encompasses bench-to-bedside research from skin biology through rehabilitation, quality of life, and reintegration outcomes.

Supports shorter-term research in cancer control and population sciences, including epidemiology, survivorship, health behaviors, healthcare delivery, digital health, data science, implementation science, and statistical methods. Best suited for innovative, focused projects that can generate impactful findings and advance population-level cancer research within a limited scope.

Supports pilot testing of patient navigation models that divert non-urgent mental health needs from emergency departments by assessing acuity, supporting caregivers, and connecting families to appropriate services. Intended for established models with limited evidence or development and pilot testing of model components, rather than larger-scale or fully powered studies.

Supports planning for future large-scale eye and vision clinical trials or epidemiologic studies that address major causes of blindness, impaired vision, sight-threatening conditions, or vision rehabilitation needs. Funds protocol development, Manual of Procedures preparation, feasibility work, and recruitment planning. Clinical trial not allowed.

Supports vision-related secondary analyses of existing human data only—such as clinical trial, epidemiologic, EHR, registry, claims, or merged patient-level datasets—to address new questions distinct from the original study aims, with no new data collection or animal-data analysis allowed.

Funds research to investigate and mitigate preanalytical variability challenges in clinical assay development using tumor tissue biopsies, liquid biopsies, and other biospecimens. The goal is to standardize biospecimen handling practices and expedite biomarker clinical assay development through evidence-based practices.

Supports investigator-initiated Program Project (P01) applications addressing scientific areas relevant to the NHLBI mission, including the biology and diseases of the heart, blood vessels, lung, blood, blood resources, and sleep disorders. This active NIH/NHLBI grant program (PAR-24-065) accepts applications on a rolling basis with multiple review cycles.

Supports new investigators in dental, oral, and craniofacial research with up to 2 years and $200,000 direct costs total ($100,000/year) for pilot, feasibility, or developmental projects meant to generate preliminary data for a later R01 or equivalent, and it does not allow clinical trials.

NIH Parent R21 exploratory/developmental research grant for early-stage, high-impact malaria research concepts. Standard NIH deadlines apply.

Supports investigator-initiated, hypothesis-driven research projects across a wide range of health-related scientific areas that align with the missions of participating NIH Institutes and Centers, provided the proposed work does not include clinical trials. It is best suited to well-developed projects with strong significance, scientific rigor, feasibility, and the appropriate expertise and environment to generate a sustained impact in their field.

Supports investigator-initiated research projects that include at least one clinical trial and align with the scientific missions of participating Institutes and Centers, spanning a broad range of health-related topics and study types. It is best suited to well-developed projects with strong significance, rigor, feasibility, and clinical trial design, especially those that fit a participating IC’s priorities and, where relevant, address mechanistic questions rather than only efficacy or implementation.

Supports innovative research in clinical informatics to develop tools and methods that improve healthcare delivery, decision-making, and patient outcomes. It emphasizes scalable, data-driven approaches that transform diverse health data into actionable knowledge across clinical settings.

Supports early stage investigators (ESI) pursuing innovative research projects that represent a change in research direction, with no preliminary data required, through the Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed). This active NIH grant (PAR-25-322) provides R01 funding to ESI applicants pursuing basic or applied biomedical research without clinical trials.

Supports innovative, high-impact research to prevent, detect, and resolve Lyme disease and other tick-borne diseases for Service Members, Veterans, their Families, and the American public. Award mechanisms include Idea Development Award (with Career Development Option) and Therapeutic/Diagnostic Research Award.

Supports human invasive neural recording and stimulation studies to investigate neural circuitry underlying mental health disorders using approaches such as intraoperative monitoring or implanted devices. Best suited for multidisciplinary, translational projects integrating electrophysiology and behavior with strong neuroethical considerations to inform future therapies.

Seeks development and demonstration of an autonomous closed-loop mechanical ventilation system for prolonged field care and aeromedical evacuation in austere military environments. Supports FDA-registered medical device companies with in-house ventilator manufacturing capabilities to mature physiological control algorithms, define system architecture, and complete Investigational Device Exemption (IDE) submission activities ahead of full-scale system development.

Solicit feedback from industry, academia, and other stakeholders to assist BARDA in understanding the existing capabilities to assume ownership of available equipment and leverage those assets to manufacture an emergency autoinjector platform, featuring a novel glass-free, collapsible, primary drug container (PDC) with the final intent to develop a new drug delivery device or platform.

Funds development of the first minimally invasive, brain-connected hearing restoration platform that reads and writes auditory information directly with the brain's auditory cortex, treating hearing loss as a neurological condition rather than an ear-only problem. Supports integrated, multidisciplinary teams advancing three technical areas—intracortical devices, dynamic sound modulation, and auditory read & write algorithms—to create closed-loop systems that reduce background noise in real time, adapt to listener intent, and restore clearer, more effortless hearing across mild to severe hearing loss.

The Concept Award supports highly innovative, untested concepts in vascularized composite allotransplantation (VCA); letter of intent required, no preliminary data, no clinical trials.